PDCD1 and cancer: To further improve the clinical outcome of chemokine receptor-directed CAR-T therapy on solid tumors, combinations with other therapies such as anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) or oncolytic virus treatment are worth exploring in efforts to develop multi-modality approaches to cancer treatment.